Clinical Trials
34 trialsExpanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
Memorial Sloan Kettering Cancer Center
Individual Patient Compassionate Use of Nirogacestat
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma
University of Florida
Compassionate Use of Ubamatamab
Regeneron Pharmaceuticals
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
KEAP
Karyopharm Therapeutics Inc
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
USWM, LLC (dba US WorldMeds)
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Leap Therapeutics, Inc.
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
Expanded Access of Vigil in Solid Tumors
Gradalis, Inc.
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
The University of Texas Health Science Center at San Antonio
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Eli Lilly and Company
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Ipsen
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
Advenchen Laboratories, LLC
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Deciphera Pharmaceuticals, LLC
Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Jonsson Comprehensive Cancer Center
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
University of Colorado, Denver
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
SARC021C: A Continuation Study of TH-CR-406/SARC021
Sarcoma Alliance for Research through Collaboration
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Bayer
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
CytRx
MACS2226
Novartis
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
Bayer
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
University of Texas Southwestern Medical Center